KURA Stock Cash Flow Statements

Kura Oncology Quarterly Cash Flow Statements Chart

Quarterly

Annual

Operating Cash Flow

Investing Cash Flow

Financing Cash Flow

Free Cash Flow

Capital Expenditure

Kura Oncology Quarterly Cash Flow Statements Table

Quarterly

Annual

Unit: USD	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30	2023-06-30	2023-03-31	2022-12-31	2022-09-30	2022-06-30	2022-03-31	2021-12-31	2021-09-30	2021-06-30	2021-03-31	2020-12-31	2020-09-30	2020-06-30	2020-03-31	2019-12-31	2019-09-30	2019-06-30	2019-03-31	2018-12-31	2018-09-30	2018-06-30	2018-03-31	2017-12-31	2017-09-30	2017-06-30	2017-03-31	2016-12-31	2016-09-30	2016-06-30	2016-03-31	2015-08-22	2015-06-30	2015-03-31	2014-03-31	2013-12-31	2013-11-16	2011-09-30	2011-06-30	2011-03-31	2010-12-31	2010-09-30	2010-06-30	2010-03-31	2009-09-30	2009-06-30	2009-03-31

operating activities
net income	-66,122,000	-57,429,000	-19,217,000	-54,404,000	-50,837,000	-49,525,000	-42,786,000	-38,602,000	-37,174,000	-34,069,000	-33,114,000	-35,504,000	-34,769,000	-32,453,000	-32,743,000	-33,366,000	-33,663,000	-30,694,000	-26,159,000	-23,769,000	-20,487,000	-19,210,000	-17,865,000	-16,392,000	-14,943,000	-13,940,000	-16,097,000	-15,007,000	-14,739,000	-14,604,000	-10,748,000	-9,333,000	-7,820,000	-7,533,000	-7,347,000	-6,926,000	-6,661,000	-6,626,000	-6,090,000	-5,585,000	-4,476,000		-9,750
adjustments to reconcile net income to net cash from operating activities:
share-based compensation expense	6,949,000	7,842,000	8,631,000	8,324,000	8,430,000	8,512,000	7,167,000	7,090,000	6,987,000	6,838,000	6,805,000	6,355,000	6,508,000	6,650,000	6,397,000	6,114,000	5,993,000	5,075,000	3,742,000	3,360,000	2,552,000	3,153,000	2,439,000	2,452,000	2,249,000	2,269,000	1,716,000	2,523,000	2,236,000	2,179,000	1,446,000	1,175,000	1,030,000	894,000	586,000	584,000	429,000	490,000	534,000	485,000	644,000
amortization of premium and accretion of discounts on short-term investments	-2,520,000	-2,662,000
depreciation expense	224,000	241,000	204,000	208,000	202,000	234,000	214,000	216,000	213,000	206,000	206,000	193,000	183,000	177,000	166,000	160,000	124,000	108,000	108,000	74,000							0	1,000	4,000	5,000	7,000	7,000	8,000	8,000	8,000	8,000	7,000	8,000	7,000	3,000	3,000
non-cash interest expense	138,000	133,000	140,000	134,000	127,000	122,000	119,000	122,000	121,000	115,000					0	0											17,000	53,000	57,000	57,000	56,000	30,000	16,000	16,000	15,000	16,000
changes in operating assets and liabilities
prepaid expenses and other current assets	-7,512,000	-1,039,000	-9,542,000	357,000	2,464,000	-2,189,000	-2,534,000	800,000	1,883,000	-2,109,000	1,352,000	912,000	-2,569,000	-2,630,000	1,131,000	678,000	694,000	-2,860,000	-474,000	130,000	1,115,000	-1,482,000	-547,000	-396,000	-288,000	146,000	825,000	-256,000	-402,000	-624,000	-12,000	278,000	-53,000	-409,000	161,000	159,000	158,000	-510,000	134,000
operating lease right-of-use and other long-term assets	-1,169,000	-1,753,000	685,000	-508,000	539,000	231,000	-1,463,000	276,000	317,000	185,000
receivable from contracts with collaborators	44,172,000	-46,686,000
contract liabilities	-10,831,000	34,594,000
accounts payable and accrued expenses	7,525,000	-5,427,000	12,702,000	5,676,000	-50,000	-3,128,000	7,646,000	3,932,000	4,113,000	-5,364,000	-1,560,000	6,350,000	-341,000	-5,251,000	31,000	139,000	-1,236,000	-1,452,000	3,684,000	2,530,000	1,854,000	-2,391,000	1,804,000	2,176,000	-1,204,000	-1,920,000	3,565,000	723,000	374,000	440,000	2,433,000	1,675,000	586,000	-1,088,000	497,000	856,000	215,000	-1,097,000	1,179,000	1,292,000	90,000
other long-term liabilities	369,000	259,000	235,000	210,000	144,000	169,000	62,000	29,000	33,000	13,000	17,000	83,000	-37,000	121,000	19,000	61,000	-146,000	46,000	50,000	234,000	-130,000	59,000	83,000	57,000	54,000	16,000	66,000	56,000	54,000	58,000	52,000	57,000	-38,000	147,000	113,000	30,000			-1,000
net cash from operating activities	-28,777,000	-71,927,000	269,131,000	-43,440,000	-42,530,000	-48,844,000	-34,308,000	-29,027,000	-25,617,000	-35,872,000	-26,530,000	-21,010,000	-30,341,000	-32,181,000	-23,366,000	-24,594,000	-28,074,000	-28,517,000	-18,308,000	-16,966,000	-14,734,000	-19,822,000	-13,933,000	-12,145,000	-14,431,000	-14,251,000	-10,211,000	-13,001,000	-12,592,000	-12,851,000	-7,474,000	-6,235,000	-6,110,000	-8,622,000	-6,738,000	-5,472,000	-5,825,000	-7,314,000	-4,430,000	-3,767,000	-4,123,000	-400	-4,012
capex	-1,458,000	-292,000	-372,000	0	-16,000	-84,000	-16,000	-20,000	-96,000	-36,000	-12,000	-381,000	-184,000	-49,000	-102,000	-723,000	-291,000	-31,000	-275,000	-665,000	-720,000	-511,000	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-22,000	-17,000	-10,000	0	0
free cash flows	-30,235,000	-72,219,000	268,759,000	-43,440,000	-42,546,000	-48,928,000	-34,324,000	-29,047,000	-25,713,000	-35,908,000	-26,542,000	-21,391,000	-30,525,000	-32,230,000	-23,468,000	-25,317,000	-28,365,000	-28,548,000	-18,583,000	-17,631,000	-15,454,000	-20,333,000	-13,933,000	-12,145,000	-14,431,000	-14,251,000	-10,211,000	-13,001,000	-12,592,000	-12,851,000	-7,474,000	-6,235,000	-6,110,000	-8,622,000	-6,738,000	-5,472,000	-5,825,000	-7,314,000	-4,452,000	-3,784,000	-4,133,000	-400	-4,012
investing activities
purchases of short-term investments	-114,600,000	-268,714,000
maturities of short-term investments	174,999,000	167,597,000
purchases of property and equipment	-1,458,000	-292,000	-372,000	0	-16,000	-84,000	-16,000	-20,000	-96,000	-36,000	-12,000	-381,000	-184,000	-49,000	-102,000	-723,000	-291,000	-31,000	-275,000	-665,000	-720,000	-511,000																	-22,000	-17,000	-10,000
net cash from investing activities	58,941,000	-101,409,000	-94,955,000	45,535,000	43,167,000	-95,337,000	42,195,000	8,559,000	-46,326,000	11,129,000	-47,318,000	71,810,000	33,097,000	-24,962,000	74,061,000	22,545,000	-37,221,000	-186,220,000	-60,190,000	-45,520,000	-21,687,000	27,461,000	-15,257,000	-55,752,000	8,876,000	15,808,000	4,618,000	-58,061,000	3,857,000	-29,714,000	-4,091,000	-36,294,000	7,433,000	9,534,000	9,680,000	143,000	-5,842,000	8,197,000	-3,891,000	-26,277,000	-10,000
financing activities
proceeds from issuance of stock under equity plans	515,000	143,000	807,000	2,202,000	3,040,000	2,555,000	691,000	84,000			567,000	880,000
proceeds from issuance of common stock and pre-funded warrants, net of offering costs				0	0	145,814,000		0
net cash from financing activities	515,000	143,000	806,000	2,202,000	3,040,000	148,369,000	691,000	84,000			34,713,000	880,000	2,669,000	303,000	794,000	2,258,000	-6,566,000	79,000	327,036,000	4,683,000	137,368,000	247,000	583,000	559,000	109,857,000	102,000	1,144,000	73,972,000	-125,000	57,650,000	-338,000	53,711,000	189,000	5,000	0	0			-252,000	-3,739,000	56,580,000		0	0				25,000	0			0
net increase in cash and cash equivalents	30,679,000	-173,193,000	174,982,000	4,297,000	3,677,000	4,188,000																	-28,607,000	-67,338,000	104,302,000	1,659,000	-4,449,000	2,910,000	-8,860,000	15,085,000	-11,903,000	11,182,000	1,512,000	917,000	2,942,000	-5,329,000	-4,214,000	883,000	-8,573,000			-400	-4,012	-8,125	-3,100	-15,379	-2,264	24,644	-3,506	-5,235	-147	-3,744	9,367	-100
cash and cash equivalents at beginning of period	0	224,462,000	0	0	0	37,318,000	0																0	0	0	16,119,000	0	0	0	11,433,000	0	0	0	9,725,000	0	0	0	15,443,000	0				0
cash and cash equivalents at end of period	30,679,000	51,269,000	174,982,000	4,297,000	3,677,000	41,506,000	8,578,000																-28,607,000	-67,338,000	104,302,000	17,778,000	-4,449,000	2,910,000	-8,860,000	26,518,000	-11,903,000	11,182,000	1,512,000	10,642,000	2,942,000	-5,329,000	-4,214,000	16,326,000	-8,573,000				-4,012
changes in operating assets and liabilities:
proceeds from issuances of common stock and pre-funded warrants, net of offering costs
proceeds from long-term debt
payment of fees related to issuance of long-term debt
supplemental disclosure of cash flow information
interest paid																															161,000	161,000	157,000	148,000
supplemental non-cash disclosures
warrants issued in connection with debt facility
amortization of premium and accretion of discounts on marketable securities				-3,437,000	-3,549,000	-3,270,000	-2,733,000	-2,890,000	-2,110,000	-1,687,000	-654,000	370,000	794,000	1,100,000	1,216,000	1,188,000	1,137,000	850,000									-636,000	-596,000	-428,000	-275,000
purchases of marketable securities				-61,729,000	-161,673,000	-195,063,000	-99,689,000	-96,671,000	-139,629,000	-73,835,000	-106,123,000	-56,953,000	-56,179,000	-51,400,000	-16,337,000	-76,232,000	-129,930,000	-223,158,000	-128,020,000	-96,125,000	-85,544,000	-11,274,000	-30,747,000	-94,952,000	-51,024,000	-50,848,000	-33,982,000	-96,611,000	-30,643,000	-76,207,000	-21,381,000	-59,894,000	-8,817,000	-10,543,000	-15,220,000	-17,762,000	-19,442,000	-4,003,000	-3,869,000
maturities of marketable securities				107,264,000	204,856,000	99,810,000	141,900,000	105,250,000	93,399,000	85,000,000	58,817,000	129,144,000	89,460,000	26,487,000	90,500,000	99,500,000	93,000,000	36,969,000									38,600,000	38,550,000	34,500,000	46,493,000	17,290,000	23,600,000	16,250,000	20,077,000	24,900,000	17,905,000	13,600,000	12,200,000
income from extinguishment of debt
repayment of long-term debt															0	0	-6,500,000	-750,000									-250,000	-750,000
payment of fees related to extinguishment of debt															0	0
net decrease in cash, cash equivalents
supplemental disclosure of cash flow information:
supplemental non-cash disclosures:
net decrease in cash, cash equivalents and restricted cash									22,065,000	-24,743,000			5,425,000	-56,840,000
cash, cash equivalents and restricted cash at beginning of period									0	52,012,000	0	0	0	90,882,000	0	0	0	325,703,000	0	0	0	26,135,000
cash, cash equivalents and restricted cash at end of period									22,065,000	27,269,000	-39,135,000	51,680,000	5,425,000	34,042,000	51,489,000	209,000	-71,861,000	111,045,000	248,538,000	-57,803,000	100,947,000	34,021,000
proceeds from issuances of common stock
net increase in cash, cash equivalents and restricted cash											-39,135,000				51,489,000	209,000	-71,861,000	-214,658,000	248,538,000	-57,803,000	100,947,000	7,886,000
loss on extinguishment of debt																0
other long-term assets												231,000	-110,000	105,000	417,000	432,000	-1,588,000	410,000	373,000	299,000	373,000	160,000	133,000	71,000	-82,000	-239,000	-149,000	-313,000	121,000	-163,000	-388,000	-88,000	171,000	-288,000	-429,000	-274,000	-23,000	74,000	-159,000
proceeds from issuance of stock under equity incentive plan														303,000
proceeds from exercises of stock options and purchases under employee stock purchase plan															794,000	2,258,000
proceeds from issuance of common stock																				-180,000				-213,000				74,520,000	0	57,650,000	-4,000	53,524,000							-255,000	-3,739,000	51,580,000
proceeds from exercise of stock options																		829,000				247,000				102,000		202,000			10,000	187,000	30,000	5,000
maturities and sales of marketable securities																			68,105,000	51,270,000	64,577,000	39,246,000	15,490,000	39,200,000	59,900,000	66,656,000
proceeds from issuance of long-term debt																																			0	0
amortization of premium and accretion of discount on marketable securities																				176,000	-24,000	-110,000		-128,000	-319,000	-540,000
proceeds from exercise of stock options and purchases under employee stock purchase plan																				4,863,000			604,000	772,000
accounts receivable, related party																						-1,000	17,000	64,000	84,000	45,000	8,000	-2,000	27,000	-41,000	-7,000	95,000	37,000	-46,000	-34,000	25,000	120,000	24,000	-7,000	-24,000	-318,000
loss on debt extinguishment
payment of fee related to long-term debt
other long-term assets, related party																								57,000	49,000	57,000
accounts payable and accrued expenses, related party																								-106,000	-31,000	-145,000	-24,000	-183,000	104,000	117,000	-126,000	-55,000	-31,000	-342,000	-318,000	34,000	-141,000	258,000
amortization of discount on marketable securities																																-76,000	-16,000	19,000	10,000	16,000	38,000	65,000	67,000
non-cash license fee expense																																							0	0	500,000
change in value of derivative liability																																							-39,000
non-cash interest expense, related party
proceeds from issuance of convertible notes
proceeds from issuance of convertible notes, related party
conversion of convertible notes and related accrued interest to common stock																																							0	0	4,327,000
conversion of convertible notes and related accrued interest to common stock, related party																																							0	0	3,288,000
proceeds from issuance of convertible notes payable																																							0	0	5,000,000
proceeds from issuance of convertible notes payable, related party
proceeds from issuance of restricted stock awards
supplemental disclosure of non-cash financing activities:
financing costs included in accounts payable and accrued expenses																																								-3,282,000	3,535,000
non-cash accrued interest expense																																							0	0	37,000
non-cash accrued interest expense, related party
long-term liabilities
accounts payable, related party																																									927,000
proceeds from issuance of notes payable, related party
non-cash accrued interest expense, related parties																																								1,000	41,000
prepaid expenses																																									-664,000
other liabilities																																									-907,000
net increase in cash																																									52,447,000
cash at beginning of period																																									1,124,000
cash at end of period																																									53,571,000
•
net cash (used in) investing activities
decrease (increase) in prepaid expenses
increase in accounts payable																																											-300
increase in accrued interest																																											1,663
increase in accrued expenses
proceeds from notes payable, stockholders																																											0
payments on notes payable, stockholders
deferred tax asset:
capitalized formation costs
net operating income carryforward
valuation allowance
net deferred tax asset recognized
increase in prepaid expenses
1.
net cash (used in) operating activities																																													-3,100	-15,379	-2,264	-356	-3,506	-15,235	-147	-3,744	-15,633	-100

We provide you with 20 years of cash flow statements for Kura Oncology stock, allowing you to gain comprehensive visibility into the fundamentals of the company. Our detailed breakdowns include key financial metrics such as operating cash flows, cash levels, capital expenditures, profits, stock-based compensations and profit margins. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of Kura Oncology stock. Explore the full financial landscape of Kura Oncology stock with our expertly curated income statements.

The information provided in this report about Kura Oncology stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.